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Abstract
Introduction: Breast cancer is a common disease with distinct tumor subtypes phenotypically characterized by ER and
HER2/neu receptor status. MiRNAs play regulatory roles in tumor initiation and progression, and altered miRNA expression
has been demonstrated in a variety of cancer states presenting the potential for exploitation as cancer biomarkers. Blood
provides an excellent medium for biomarker discovery. This study investigated systemic miRNAs differentially expressed in
Luminal A-like (ER+PR+HER2/neu-) breast cancer and their effectiveness as oncologic biomarkers in the clinical setting.
Methods: Blood samples were prospectively collected from patients with Luminal A-like breast cancer (n = 54) and controls
(n = 56). RNA was extracted, reverse transcribed and subjected to microarray analysis (n = 10 Luminal A-like; n = 10 Control).
Differentially expressed miRNAs were identified by artificial neural network (ANN) data-mining algorithms. Expression of
specific miRNAs was validated by RQ-PCR (n = 44 Luminal A; n = 46 Control) and potential relationships between circulating
miRNA levels and clinicopathological features of breast cancer were investigated.
Results: Microarray analysis identified 76 differentially expressed miRNAs. ANN revealed 10 miRNAs for further analysis (miR-
19b, miR-29a, miR-93, miR-181a, miR-182, miR-223, miR-301a, miR-423-5p, miR-486-5 and miR-652). The biomarker potential of
4 miRNAs (miR-29a, miR-181a, miR-223 and miR-652) was confirmed by RQ-PCR, with significantly reduced expression in
blood of women with Luminal A-like breast tumors compared to healthy controls (p = 0.001, 0.004, 0.009 and 0.004
respectively). Binary logistic regression confirmed that combination of 3 of these miRNAs (miR-29a, miR-181a and miR-652)
could reliably differentiate between cancers and controls with an AUC of 0.80.
Conclusion: This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From
an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The
expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-
specific breast tumor detection.
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Introduction
Breast cancer is a prevalent disease, accounting for significant
morbidity and mortality with a worldwide incidence of over
1,300,000 women [1]. It is the commonest female malignancy in
almost all European countries and in North America and leading
cause of female cancer mortality. Breast cancer is a heterogeneous
disease, with distinct tumor phenotypes reflecting a spectrum of
underlying molecular alterations and initiating events [2]. Analysis
of gene expression patterns governing these events has resulted in
the classification of breast tumors into subtypes broadly deter-
mined by expression of the estrogen receptor (ER), progesterone
receptor (PR) and human epidermal growth factor receptor
(HER2/neu). Targeted therapies including hormonal therapy for
ER positive tumors and trastuzumab to inhibit HER2/neu
signaling have become the major components of adjuvant breast
cancer management. Consequently, when diagnosed and treated
early, breast cancer is highly curable. Despite these advances,
hematogenous spread of malignant cells from the primary tumor
to distant organs with subsequent proliferation into metastases
remains the leading cause of death for breast cancer patients [3].
Further insight into the molecular mechanisms underlying
tumorigenic transformation is clearly warranted for the identifi-
cation of additional molecular predictors and disease biomarkers
in the clinical management of breast cancer.
Much current cancer research is focused on the identification of
circulating cancer-specific biomarkers for application to disease
diagnostics, as well as predicting and monitoring response to
disease and tumor recurrence. There are no reliable circulating
biomarkers for breast cancer. Mammography is the most
widespread screening tool, with a definitive diagnosis requiring
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an invasive tissue biopsy. This prevalent disease is in need of a
minimally invasive biomarker which may be used in combination
with radiological imaging to facilitate early subtype specific tumor
diagnosis. Blood presents an excellent medium for biomarker
discovery; it is minimally invasive and simple to obtain during
routine clinical examination. Moreover, blood circulates through-
out the body delivering nutrients and carrying proteins (including
miRNAs), hormones and cells while eliminating waste substances,
thereby reflecting the summation of physiological and pathological
processes occurring in an individual at any one time.
Mi(cro)RNAs have shown much potential as cancer-specific
biomarkers. MiRNAs regulate gene expression at the post-
transcriptional level and are intimately linked with the cancer
state; Firstly, miRNA expression has a causal effect on tumour-
igenesis, acting as oncogenes and tumor suppressor genes and
secondly, altered miRNA expression occurs as a result of the
carcinogenic process. In breast cancer, altered tissue miRNA
expression patterns have been shown to correlate with molecular
subtype and hormonal receptor status [4,5]. MiRNAs were
originally studied in tissue, but several studies have demonstrated
that tumor-specific miRNAs are detectable in the circulation [6–
8]. These studies allude to the promising role of circulating
miRNAs as biomarkers for detection of disease. Furthermore,
speculation that circulating miRNA profiles could reflect not only
the tumor tissue-type, but also the intrinsic molecular subtype thus
acting as a fluid biopsy would be particularly valuable in breast
cancer where management, even immediately following diagnosis,
is governed by hormonal and HER2/neu receptor status, largely
conveying molecular subtype.
Luminal A is the most common subtype, including over 70% of
breast cancers. Confirmation of Luminal A subtype is performed
using mRNA expression analysis however phenotypically Luminal
A-like tumors are characterized as hormone receptor positive and
HER2/neu negative. These tumors are frequently screen detected,
node negative and therefore associated with a good prognosis.
Recent advances such as the development of the Oncotype DXH
test strive to prevent overtreatment of this common subtype by
identifying women at high risk of recurrence for adjuvant
chemotherapy.
The aim of this study was to utilize microarray profiling to
identify circulating miRNAs that are differentially expressed in
women with Luminal A-like breast cancer (ER positive, PR
positive, HER2/neu negative) in comparison to healthy controls, to
validate candidate miRNA expression using RQ-PCR, investigate
their expression level in association with common clinicopatho-
logical parameters, and to study their effectiveness as circulating
diagnostic biomarkers in the clinical setting.
Methods
Study Cohort and Sample Collection
Blood samples were prospectively collected from 110 women;
this included 54 consecutive patients with a new diagnosis of
Luminal A-like breast cancer and 56 healthy control participants.
All patients had histologically confirmed Luminal A-like breast
cancer; Hormone receptor positive and HER2/neu negative.
Definitive confirmation of Luminal A subgroup would have
required mRNA expression profiling which was not routinely
performed or available at our institution. Healthy control blood
samples were collected from women residing in the same
catchment area as the cancer cases. These women were
interviewed by a clinician in advance of sample collection to
ensure that there was no personal history of malignancy or current
inflammatory or infectious condition. Venous non-fasting whole
blood samples were collected in BD vacutainersH containing
18 mg dipotassium EDTA anticoagulant (BD-Plymouth, PL6
7BP, UK). Microarray profiling was performed on RNA derived
from blood on 10 of the above patients and 10 controls, the
clinicopathological details of which are presented in Table 1. The
remaining 44 cases and 46 controls were used to independently
validate microarray findings. Clinicopathological details of the
validation group are shown in Table 2. Tissue specimens both
tumor (n= 11) and tumor-associated normal (TAN, n= 10) were
prospectively collected from patients with Luminal A-like breast
cancer at the time of surgical resection. Tissue samples were
collected in RNAlaterH RNA stabilization reagent (Qiagen, UK)
prior to cryopreservation at 280uC. Clinicopathological details of
this cohort are included in Table 3.
Ethics Statement
Ethical approval was granted by the Clinical Research Ethics
Committee, Galway University Hospital. Written informed
consent was obtained from all study participants.
RNA Extraction
Total RNA was extracted from 1 ml of blood using TRI
Reagent BD (Molecular Research Centre, Inc) as previously
described [9]. RNA concentration and integrity were examined by
NanoDrop spectrophotometry (NanoDrop ND-1000 Technolo-
gies Inc., DE, USA) and Agilent Bioanalyzer RNA 6000
NanoChip Kit Series II (Agilent Technologies, Germany) analysis,
respectively.
MiRNA Microarray Profiling
Expression profiling of circulating miRNAs was performed for
20 samples as described above using TaqMan human miRNA
arrays and assays in accordance with the manufacturer’s
instructions (Taqman Low Density Array Human microRNA,
Applied Biosystems, Foster City, CA, USA). In brief, total RNA
was reverse transcribed using Megaplex primer pool A (Applied
Biosystems) which contained sequence-specific primers for 381
specific miRNAs plus 3 controls (pool A). An additional panel of
384 miRNAs (381 miRNAs and 3 controls, pool B) was performed
on a subset of 4 cancers and 4 controls. Real-time quantitative
PCR was performed for 667 miRNAs, using A and B microfluidic
cards, each containing primers and probes for 381 specific
miRNAs plus 3 controls and thermal-cycled on an Applied
Biosystems 7900 HT instrument. MiRNA expression data are
available from the National Center for Biotechnology Gene
Expression Omnibus (GEO) at accession number GSE46355.
Microarray Data Analysis
Within this study normalized miRNA array data were analyzed
within a nonlinear ANN based data mining algorithm to identify
those with altered expression in Luminal A-like breast cancer. This
method comprised a feed-forward back-propagation algorithm
utilizing a three layer architecture, a sigmoid transfer function, 2
hidden nodes and early stopping on unseen data full details are
described by Lancashire et al [10]). Monte Carlo Cross validation
was applied to the modeling approach to determine the
performance of the miRNA probes on a randomly selected blind
subset. This approach addressed issues with false discovery by
preventing over fitting, driving the solution to one that has good
predictability for a blind population.
The performance of single miRNA probes was determined by
developing ANN models using the algorithm described above
(each using a single probe intensity from the data), to classify
MiRNA Biomarkers for Luminal A-like Breast Cancer
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between Luminal A-like breast cancer and healthy controls
(Figure 1). This process was repeated for all of the probes on the
array and their classification performance on blind data
determined. In this way a rank order of miRNAs was determined.
From this rank order the key miRNAs were taken forward for
validation.
Validation by RQ-PCR
Quantification of individual miRNAs in both blood and tissue
samples was determined by RQ-PCR using TaqMan miRNA
assays (Applied Biosystems). Ten of the most differentially
expressed miRNAs from the microarray screen were selected for
validation. Following RNA isolation, 100 ng of total RNA was
reverse transcribed using stem-loop primers and MultiScribe
reverse transcriptase. PCR reactions were performed in triplicate
in final volumes of 10 ml on 96 well plates. Each plate included an
inter assay control (IAC) to account for run-to-run variation. Plates
were run on a 7900 HT instrument (Applied Biosystems) using
standard thermal-cycling conditions.
Raw fluorescence (cycle threshold, CT) data were subsequently
calculated. High CT values indicated low miRNA expression and
vice versa. The threshold standard deviation for intra- and inter-
assay replicates was 0.28. PCR amplification efficiencies (E) were
calculated for each miRNA and Taqman miRNA assay using the
formula E= (1021/slope21)6100, using the slope of the semi-log
regression plot of Ct versus log input of cDNA (10-fold dilution
series of five points). A threshold of 10% above or below 100% was
adopted. CT values were scaled to lowest expressing sample and
normalized to miR-16, which has been shown to be stably
expressed in breast cancer and is the most widely used endogenous
control miRNA for breast cancer thus far [9,11]. MiRNA
expression was calculated by the comparative cycle threshold
(DCT) method, using qbase
PLUSH software (Biogazelle, NV,
Belgium).
Statistical Analysis
Statistical analysis was performed using Minitab version 16.0
(Minitab Ltd, Coventry UK). The Kolmogorov-Smirnov test for
normality was conducted. Data were log transformed (log10) for
analysis when non-normal distribution was identified. Significance
and associations of circulating miRNA levels were determined
using the Mann-Whitney U test, t-test, ANOVA, Spearman’s Rho
or Pearson correlation, as appropriate. Results with p-value less
than 0.05 were deemed to be significant. Binary logistic regression
analysis was used and receiver operating characteristic (ROC)
curves were generated to evaluate the ability of chosen miRNAs to
distinguish between cancer cases and controls. This was performed
both individually and for combinations of miRNAs.
Results
Identification of Dysregulated miRNAs in Luminal A-like
Breast Cancer
The ANN data mining algorithm identified 76 miRNAs with
detectable and altered expression in blood of patients with
Luminal A-like breast cancer compared to healthy controls (Table
S1).
Validation of Microarray
To further evaluate the expression patterns of individual
miRNAs derived from the microarray dataset, real-time quanti-
tative PCR was performed. A subset of three candidate miRNAs
was chosen for sample to sample expression analysis and in most
cases revealed good correlation between the microarray profiling
data and RQ-PCR validation (Figure S1). Expression of ten of the
most deregulated miRNAs was confirmed in an independent
cohort of blood from patients with luminal A-like breast cancer
(n = 44) and healthy controls (n = 46). MiRNA expression levels
were also measured in tumor tissue derived from patients with
Luminal A-like breast tissue. The miRNAs selected for validation
and results obtained are outlined in Table 4. Two miRNAs (miR-
181a and miR-652) were found to be over-expressed in the
microarray and were down-regulated in the circulation of women
with Luminal A-like breast tumors in the validation group
(p = 0.004, and 0.009, respectively, Figure 2). Both miR-181a and
miR-652 miRNAs were also under-expressed in Luminal A-like
tumor tissue compared to TAN (p= 0.019 and p,0.001,
respectively Figure 2). MiR-29a and miR-223 were under-
expressed in the circulation of those with Luminal A-like breast
cancer compared to healthy controls, in both the array and the
validation cohorts (p,0.001 and p= 0.004, Figure 2).
Table 1. Clinicopathological patient data for blood samples analyzed by microarray.
Cases Age (yrs)
Inv. T size
(mm)
Whole T
size (mm)
Histological
Subtype
Nodal
Status Grade
UICC
Stage ER PR HER2/neu Controls* Age (yrs)
1 70 22 22 Inv. Muc. – 2 1 + + – 1 81
2 52 15 15 Inv. Ductal – 2 2 + + – 2 61
3 60 13 20 Inv. Ductal – 2 2 + + – 3 82
4 50 22 22 Inv. Ductal – 2 1 + + – 4 76
5 46 38 38 Inv. Ductal + 1 2 + + – 5 74
6 59 120 120 Inv. Ductal + 2 3 + + – 6 87
7 56 53 53 Inv. Lobular + 2 2 + + – 7 94
8 55 61 61 Inv. Ductal + 2 3 + + – 8 94
9 44 45 45 Inv. Ductal – 2 2 + + – 9 96
10 75 50 60 Inv. Ductal + 2 3 + + – 10 72
Yrs, Year; mm,Millimeters; Inv. T size, Invasive Tumor size; UICC, Stage of breast tumor according to the International Union Against Cancer staging criteria; ER, Estrogen
receptor; PR, Progesterone receptor: HER2/neu, Human epidermal growth factor receptor; –, negative; +, positive; NA not applicable. *All control subjects had no
personal or family history of breast or ovarian cancer and were clinically well at the time of sampling.
Luminal A-like is phenotypically defined as ER positive, PR positive, HER2/neu negative.
doi:10.1371/journal.pone.0087032.t001
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Association/Relationship between miRNA Expression and
Clinicopathological Parameters
MiRNA (miR-29a, miR-181a and miR-652) expression data was
compared with clinicopathological variables, namely grade, nodal
status, tumor size and stage of disease. MiR-29a, miR-181a and
miR-652 were significantly down-regulated in the blood of patients
compared to controls, irrespective of tumor grade, nodal status or
stage of disease (Table 5). Altered expression in both early and late
stage disease is an important biomarker characteristic. Interest-
ingly, miR-181a was significantly down-regulated in the blood of
patients with node positive disease compared to healthy controls
(p = 0.006) but not node negative disease (p = 0.09). There was no
difference in miR-181a expression between node positive or node
negative disease. There was a negative correlation between miR-
181a expression and invasive tumor size (Pearson correlation
coefficient r =2429, p = 0.059).
Biomarker Potential of miRNAs
The evident dysregulation of miR-29, miR-181a and miR-652 in
the blood of women with Luminal A-like breast cancer,
irrespective of tumor stage or grade, revealed a potential role for
these miRNAs as circulating biomarkers for Luminal A-like breast
cancer detection. We compared the area under the curve (AUC)
produced from receiver operator characteristic (ROC) curve
generation using binary logistic regression analysis for each
individual miRNA and miRNA combination profiles. The best
AUC cut-off of 0.80 was generated from a combination of miR-
29a, miR-181a and miR-652, providing a sensitivity and specificity
of 77% and 74%, respectively (Figure 3). The addition of miR-223
did not improve the sensitivity or specificity profile achieved.
Discussion
Mammography is currently the gold standard screening tool for
breast cancer diagnosis; however accurate diagnosis and intrinsic
subtype confirmation requires histological evaluation from tissue
obtained at breast biopsy, an invasive procedure. The identifica-
tion of novel reliable minimally invasive breast cancer biomarkers
would represent a significant development in the clinical
management of this complex disease. The concept of a panel or
Table 2. Clinicopathological Patient Data for Blood in
Independent Validation Cohort.
Luminal A Breast Tumors Number (%) 44
Mean age, years (range) 59.86 (613.45)
Median Whole. T size (mm) 32.82 (626.30)
Missing data 11
Median Inv. T size (mm) 27.41 (620.74)
Missing data 22
Histological Subtype
Invasive ductal 35
Invasive lobular 1
Other 7
Missing 1
Nodal status
Positive 22
Negative 19
Missing 3
Grade
1 7
2 32
3 4
Missing 1
UICC stage
Stage 1 15
Stage 2 14
Stage 3 8
Stage 4 2
Missing 3
Estrogen Receptor
Positive 44 (100%)
Negative 0
Progesterone Receptor
Positive 44 (100%)
Negative 0
HER2/neu Receptor
Positive 0
Negative 44 (100%)
Subtype
Luminal A-like 44 (100%)
Controls 46
Mean Age, years (range) 44.21 (620.61)
doi:10.1371/journal.pone.0087032.t002
Table 3. Clinicopathological Patient Data for Breast Tumors.
Luminal A Breast Tumors Number (%) 11
Mean age, years (range) 54.27 (69.26)
Median Whole. T size (mm) 34.1 (642.5)
Histological Subtype
Invasive ductal 11
Grade
1 1
2 1
3 8
Missing 1
UICC stage
Stage 1 3
Stage 2 8
Estrogen Receptor
Positive 11 (100%)
Negative 0
Progesterone Receptor
Positive 11(100%)
Negative 0
HER2/neu Receptor
Positive 0
Negative 11 (100%)
Subtype
Luminal A-like 11 (100%)
doi:10.1371/journal.pone.0087032.t003
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profile of miRNAs for diagnostic purposes is a realistic approach,
as to date no single miRNA has been reported with the qualities
(sensitivity, specificity and reproducibility) for use in isolation. The
3 miRNAs identified in this study yielded a sensitivity and
specificity of 77% and 74% respectively, and could be evaluated
from blood collected during a simple blood test. Although not
perfect, this sensitivity and specificity profile exceeds that of several
currently used clinical biomarkers [12–15] and could be improved
with the combination of mammography. There is no routinely
used circulating biomarker for breast cancer detection. Carcinoma
Antigen 15-3 (CA 15-3) and Carcinoembryonic Antigen (CEA) are
circulating biomarkers. However their clinical application in
breast cancer management is, if any, confined to detecting and
monitoring disease recurrence and progression. These markers are
Figure 1. ANN architecture and algorithm as applied to data mining for miRNA markers of Luminal A-like breast cancer.
doi:10.1371/journal.pone.0087032.g001
Table 4. Candidate miRNAs for validation by RQ-PCR.
miRNA Chromosomal Location Sequence Expression
p-value
(Circulation, RQ-
PCR) *
p-value (Tissue,
RQ-PCR)*
miR-19b Chromosome 13:
92001446–92005532 (+)
UGUGCAAAUCCAUGCAAAACUGA Unchanged 0.775 NA
miR-29a Chromosome 7:
130561506–130561569 [2]
UAGCACCAUCUGAAAUCGGUUA Down 0.001 0.330
miR-93 Chromosome 7:
99691391–99691470 [2]
CAAAGUGCUGUUCGUGCAGGUAG Unchanged 0.399 NA
miR-181a Chromosome 1:
198828173–198828282 [2]
AACAUUCAACGCUGUCGGUGAGU Down 0.004 0.019
miR-182 Chromosome 7:
129410223–129410332 [2]
UUUGGCAAUGGUAGAACUCACACU Unchanged 0.355 NA
miR-223 Chromosome X:
65238712–65238821 [+]
UGUCAGUUUGUCAAAUACCCCA Down 0.004 NA
miR-301a Chromosome 17:
57228497–57228582 [2]
CAGUGCAAUAGUAUUGUCAAAGC Unchanged 0.179 NA
miR-423-5p Chromosome 17:
28444097–28444190 [+]
UGAGGGGCAGAGAGCGAGACUUU Unchanged 0.519 NA
miR-486-5p Chromosome 8:
41517959–41518026 [2]
UCCUGUACUGAGCUGCCCCGAG Unchanged 0.333 NA
miR-652 Chromosome X:
109298557–109298654 [+]
AAUGGCGCCACUAGGGUUGUG Down 0.009 0.001
Table Legend: *p-value determined by t-test.
doi:10.1371/journal.pone.0087032.t004
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Figure 2. Expression levels of (A) miR-29a (i) in the circulation of patients with Luminal A-like breast cancer versus healthy controls
and (ii) miR-29a levels in tumour and associated normal (TAN) tissue; (B) miR-181a expression (i) in the circulation of cases and
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merely elevated in 10% of stage 1 disease and 20% of stage 2
disease, precluding any usefulness in the diagnostic arena.
Early miRNA-related research mainly focused on tissue, with
several reports of aberrant miRNA expression in breast cancer
correlating with clinico-pathological variables such as stage and
hormone receptor status [5,16–20]. Furthermore, individual
miRNAs have been associated with metastatic potential of breast
tumors [21]. The rush to identify non-invasive diagnostic
biomarkers for breast cancer has resulted in a surge of interest
in circulating miRNAs. Several studies to date have evaluated
miRNA expression in blood of women with breast cancer [11,22].
Not all reports in the literature are directly comparable, as
although circulating miRNAs are analyzed in each case, three
alternative blood components have been used, namely whole
blood, serum and plasma. We chose to analyze whole blood in this
study as stability of miRNAs in EDTA-whole blood and the
potential to profile miRNAs from this medium have been
demonstrated [11,23,6]. In addition, given that circulating
miRNA research is still in its infancy, it was chosen to utilize
methods that could potentially be exploited in larger multi-centric
trials by collecting whole blood stored in a refrigerator until
transport rather than plasma or serum that requires prompt
centrifugation, alloquotting and freezing.
It has been suggested that circulating miRNAs may reflect the
presence of breast tumors but not the specific profiles of miRNAs
within the breast tumors [24,25]. In the current study, we
identified four miRNAs (miR-29a, miR-181, miR-223 and miR-652)
with dysregulated expression in the circulation of women with
Luminal A-like breast cancer. MiR-181a and miR-652 were down-
regulated in Luminal A-like breast tumor tissue, while miR-29a was
not. These findings support the hypothesis that circulating miRNA
expression profiles may not act as a direct window on tumor
activity and brings into question the mechanism by which they
enter the blood stream, in addition to their functional role, if any,
in the peripheral circulation. These processes remain poorly
understood. MiRNAs can enter the peripheral circulation
following selective secretion from tumor cells or circulating
micro-vesicles [26]. Other cells in the tumor microenvironment
can also secrete miRNAs. Meanwhile another school of thought
suggests that miRNAs may be detectable in the circulation as a
consequence of passive leakage from apoptotic and necrotic cells
[27]. In reality it is likely that both of these theories are true, with
accumulating evidence to support both plausible proposals.
Once in the circulation, miRNA transport is not uniform. Some
miRNAs are encapsulated in microvesicles, apoptotic bodies,
exosomes or high-density lipoprotein (HDL) particles while others
are in combination with proteins of the Argonaute (AGO) family
[28–30]. The protection conveyed by microparticles or in
combination with AGO proteins explains the stability of miRNAs
in nuclease rich and protease rich environments, such as the
circulation, when compared to mRNA [31]. The majority of
circulating miRNAs, as much as 90–95%, are transported in
combination with the AGO protein family [30,31]. The functional
role of miRNAs in circulation has yet to be fully elucidated; are
these tiny particles merely secreted as by-products of physiological
and pathological processes or are they circulating messengers, with
important intercellular and inter-organ cell to cell messaging
capabilities? Some recent studies allude to the potential for
exosomally-packaged miRNA to act as cell to cell signaling
molecules, during viral infection, the immune response and most
significantly cancer progression [32–34]. However, despite these
reports, it is likely that the majority of circulating extracellular
miRNAs, particularly the AGO-transported form, have no
functional role. Nonetheless, regardless of their source, their
presence, relative stability and ease of detection can be exploited
for biomarker means.
In this study ANN identified four specific miRNAs as being
significantly altered in the circulation of women with Luminal A-
like breast cancer. ANN data-mining algorithms have been shown
to provide a robust solution to issues encountered within miRNA
array data [5]. They have been shown to cope with non-linearity,
and complexity; whilst offering the ability to identify biomarkers of
high biological relevance and good predictive sensitivity and
specificity [10]. MiR-181a has previously been reported as being
controls and (ii) and in tumour and TAN tissue; (C) miR-652 expression in the circulation of cases and controls (i) and in tumour and
TAN tissue (ii).
doi:10.1371/journal.pone.0087032.g002
Table 5. miRNA expression and clinicopathological
parameters.
Clinicopathological Parameter miRNA P-value*
Stage miR-29a 0.737
miR-181a 0.058
miR-652 0.511
Grade miR-29a 0.193
miR-181a 0.924
miR-652 0.998
Nodal Status miR-29a 0.845
miR-181a 0.257
miR-652 0.845
This table demonstrates that although miR-29a, miR-181a and miR-652 are
under-expressed in women with Luminal A-like breast tumors, there is no
significant difference in miRNA expression levels in the blood of women with
breast cancer, regardless of stage of disease (1 to 5), grade of disease (1 to 3) or
nodal status (positive or negative). This is an important biomarker trait, as it
reflects miRNA expression alteration in early, as well as late stage disease.
*p-value determined by one-way ANOVA.
doi:10.1371/journal.pone.0087032.t005
Figure 3. Receiver Operator Characteristic (ROC) Curve for 3
miRNA combination (miR-29a, miR-181a and miR-652).
doi:10.1371/journal.pone.0087032.g003
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significantly under-expressed in the serum of women with breast
cancer compared to healthy controls [35]. It has also been shown
to be downregulated in tumor tissue of lung, oral, hepatocellular,
and ovarian cancers [36–39]. In addition, miR-181a was identified
as a potential prognostic factor for colorectal and gastric cancer
[40,41]. A recent study, using NGS-SOLiD sequencing followed
by validation with RQ-PCR reported miR-29a as being over-
expressed in the serum of women with breast cancer [42]. This
miRNA has been implicated in other cancers, predominantly
colorectal where it may have a role in prognostication [43,44].
MiR-223 has been reported in serum of patients with nasopha-
ryngeal carcinoma and gastric cancer [45,46]. In vitro analysis
revealed that miR-223 was detected within exosomes and increased
invasiveness of co-cultured cell lines (SKBR2 and MDA-MD-321)
[47]. In the present study, validation of miR-223 expression was
examined in fewer samples than were available for miR181a,
miR29a and miR-652 validation (29 cancers, 40 controls), however
we found it to be significantly lower in the circulation of cancer
patients, p=0.004). There are no previous reports, to our
knowledge, of a role for miR-652 as a diagnostic biomarker for
breast cancer.
Despite the rapidly evolving field of circulating miRNAs as
oncologic biomarkers, there are still a number of challenges which
much be overcome before miRNA profiling can be routinely
incorporated into the diagnostic arena. Real time is the most
common technique employed for miRNA quantification. Despite
significant technological advances in PCR instrumentation, and
levels of detection, there remains little consensus on assay design
through to data analysis. In particular, there is a lack of
concordance on protocols for data normalization.
Although these results are extremely promising, and substanti-
ate the potential application of miRNAs as biomarkers for breast
cancer, we recognize that this study has limitations. The sample
size is relatively small; larger validation analyses, involving blinded
samples are needed to confirm the clinical utility of the 3 miRNA
panel for luminal A-like breast cancer detection. Such studies
should ideally include blood samples from all breast tumor
subtypes, namely Luminal B, HER2/neu over-expressing and basal
subgroups, as well as from patients with benign breast disease.
Future studies to evaluate the mechanism of action of these
miRNAs, if any, in breast tumors and determine the exact
processes by which miR-29a, miR-181a, miR-223 and miR-652 are
shed into the circulation are also warranted.
The potential value of the miRNAs outlined in this study is not
restricted to diagnostic biomarkers for breast cancer. The realm of
miRNA-related therapeutic strategies is gaining increased mo-
mentum, particularly in hepatitis and hepatocellular carcinoma.
MiRNAs with depleted expression levels may be restored to
‘normal’ levels by viral vector encoded miRNAs or miRNA
mimetics. It seems plausible if these miRNAs have a functional
role in the tumor microenvironment, tumourigenesis could
potentially be halted or reversed by restoring their expression
levels.
Conclusions
In conclusion, this study presents 76 miRNAs with differential
expression in the circulation of women with Luminal A-like breast
cancer compared to those who do not have breast cancer. A
miRNA profile of three circulating tumor-associated miRNA
biomarkers (miR-29a, miR-181a and miR-652) for breast cancer are
identified which in combination provide a sensitivity and
specificity profile which exceeds that of several current clinical
biomarkers. A complementary test, for use in combination with
mammography would prove extremely advantageous particularly
in an era where swift diagnosis, expeditious commencement of
appropriate adjuvant treatments and surgical resection have a role
to play in ultimately improving patient outcomes. Further large
prospective studies are required, to include all breast cancer
subtypes and to elucidate the potential of miRNAs in the systemic
circulation as subtype-specific diagnostic or therapeutic breast
cancer markers.
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